Asthma biologics have substantial impact on oral steroid use

Mepolizumab use has led to a significant and sustained reduction in oral corticosteroids (OCS) use in patients with severe eosinophilic asthma, Australian research indicates. Observational data from 309 patients in the Australian Mepolizumab Registry shows that in the 48% of patients using maintenance OCS before starting the biologic, there was a gradual reduction in steroid ...